ArticleCureus2025
Hepatic Encephalopathy in the Hepato-Gastroenterology and Internal Medicine Department of General Idrissa Pouye Hospital: A Retrospective Prognostic Study of 69 Cases.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatic encephalopathy (HE) is a common and severe complication of acute or chronic liver failure. The aim of this study was to describe the epidemiological, diagnostic, therapeutic, and outcome aspects of HE in an internal medicine and hepato-gastroenterology department.
methodsThis was a retrospective descriptive study based on data collected over a six-year period (June 2017 to May 2023) at the hepato-gastroenterology and internal medicine department of Idrissa Pouye General Hospital. All patient records with diagnosed HE were collected. Data were recorded using a standardized survey form, entered, and analyzed with IBM SPSS Statistics for Windows, Version 25 (Released 2017; IBM Corp., Armonk, New York, United States). Multivariate analysis was performed using binary logistic regression with a significance level set at p<0.05.
resultsA total of 82 cases of HE were identified among 2480 patients hospitalized during the study period, corresponding to a prevalence of 3.3 %. Thirteen records were unusable, leaving 69 records for analysis. The mean age was 49 ± 16.70 years (range: 17 to 85 years). A male predominance was observed with a sex ratio of 2.45 (49 men, 71.0%). Asterixis (flapping tremor) was present in 41 patients (59.4%). HE was most often classified as West Haven stage II in 41 patients (59.4%). Cirrhosis was present in 57 patients (82.6%), with 51 of these classified as Child-Pugh C (73.9%). The predominant etiology identified among these patients was chronic hepatitis B virus infection. Associated clinical signs were dominated by edematous-ascitic decompensation in 52 patients (75.4%) and jaundice in 51 patients (73.9%). The precipitating factors most frequently associated with the HE episode were herbal medicine use in 22 patients (31.9%), spontaneous bacterial peritonitis (SBP) in 18 patients (26.1%), and gastrointestinal bleeding in 13 patients (18.8%). All patients received treatment based on lactulose and rifaximin. The outcome was marked by death in 53 cases (76.8%), with a mean delay of 7.2 days from symptom onset to death. Multivariate analysis identified a Child-Pugh score of C13 (p=0.043) and the presence of jaundice (p=0.034) as factors associated with poor prognosis.
conclusionHE most commonly occurs on a background of severe cirrhosis. Most often precipitated by herbal medicine use, SBP, or gastrointestinal bleeding, the prognosis remains poor, influenced in our study by jaundice and a Child-Pugh C score. Death typically occurs within the first week after symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.